Remote Laboratory for E-Learning of Systems on Chip and Their Applications to Nuclear and Scientific Instrumentation

Configuring and setting up a remote access laboratory for an advanced online school on fully programmable System-on-Chip (SoC) proved to be an outstanding challenge. The school, jointly organized by the International Centre for Theoretical Physics (ICTP) and the International Atomic Energy Agency (IAEA), focused on SoC and its applications to nuclear and scientific instrumentation and was mainly addressed to physicists, computer scientists and engineers from developing countries. The use of e-learning tools, which some of them adopted and others developed, allowed the school participants to directly access both integrated development environment software and programmable SoC platforms. This facilitated the follow-up of all proposed exercises and the final project. During the four weeks of the training activity, we faced and overcame different technology and communication challenges, whose solutions we describe in detail together with dedicated tools and design methodology. We finally present a summary of the gained experience and an assessment of the results we achieved, addressed to those who foresee to organize similar initiatives using e-learning for advanced training with remote access to SoC platforms

Looking for suitable rules for true random number generation with asynchronous cellular automata

Achieving true random behavior in digital systems represents both a challenge and an opportunity for high-performance true random number generation (TRNG). Asynchronous cellular automata (ACA) are interesting candidates for reconfigurable hardware implementations, but one of its main problems is the identification of the best rules for performance and quality. In this article, we propose an analytical approach to evaluate and select suitable rules for TRNG with physical implementations of ACA networks. We introduce the concept of rule reactivity as an indicator of the expected ACA average transition rate. We also propose the concept of rule disequilibrium function for probabilistic estimation of the ACA output balance. Based on these analytic tools, it is possible to identify the best rules for ACA with any number of inputs.Fil: Cicuttin, A.. The Abdus Salam; Italia. The Abdus Salam. International Centre for Theoretical Physics; ItaliaFil: de Micco, Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mar del Plata. Instituto de Investigaciones Científicas y Tecnológicas en Electrónica. Universidad Nacional de Mar del Plata. Facultad de Ingeniería. Instituto de Investigaciones Científicas y Tecnológicas en Electrónica; ArgentinaFil: Crespo, M. L.. The Abdus Salam. International Centre for Theoretical Physics; Italia. The Abdus Salam; ItaliaFil: Antonelli, Maximiliano. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mar del Plata. Instituto de Investigaciones Científicas y Tecnológicas en Electrónica. Universidad Nacional de Mar del Plata. Facultad de Ingeniería. Instituto de Investigaciones Científicas y Tecnológicas en Electrónica; ArgentinaFil: Garcia, L.. Università degli Studi di Trieste; Italia. The Abdus Salam. International Centre for Theoretical Physics; Italia. The Abdus Salam; ItaliaFil: Florian Samayoa, W.. The Abdus Salam; Italia. Università degli Studi di Trieste; Italia. The Abdus Salam. International Centre for Theoretical Physics; ItaliaFil: Silva, Agustin. The Abdus Salam. International Centre for Theoretical Physics; Italia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mar del Plata. Instituto de Investigaciones Científicas y Tecnológicas en Electrónica. Universidad Nacional de Mar del Plata. Facultad de Ingeniería. Instituto de Investigaciones Científicas y Tecnológicas en Electrónica; Argentin

Edoxaban versus warfarin in patients with atrial fibrillation

Contains fulltext : 125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)